Tulane Report: Heart Attacks Increase Men's Risk of Bone Loss and Osteoporosis
Posted on: Monday, 27 February 2006, 03:02 CST
By Anonymous
Men who have survived a heart attack are at increased risk of bone loss and osteoporosis in later life, reports Tulane University researcher Jeanette H. Magnus.We have long known that heart disease and osteoporosis have similar riskfactors but this is the first study to examine the relationship between heart-attack survivors and low bone mineral density, said Magnus. Cigarette smoking, a sedentary lifestyle and poor nutrition are risk factors common to both chronic conditions. According to our data, people who reported a previous heart attack were more likely to have low bone mineral density than those who did not report a heart attack. But when examining this association separately for men and women it was only significant for men.Magnus analyzed data from 5,050 men and women 50 to 79 years old in the Third National Health and Nutrition Examination Survey between 1988 and 1994. Researchers also found cigarette smoking, lack of physical activity and being overweight were all predictive of bone density loss in men.We recommend that men who survive heart attacks be screened for bone density loss, said Magnus. There is currently no recommendation to screen men for osteoporosis. Loss of bone density is a normal part of aging, but excessive loss puts people at risk of bone fractures and further disability.The results were published by Osteoporosis International.
(Copyright 2006 Dolan Media Newswires)
Source: New Orleans CityBusiness
Related Articles
- deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
- Denosumab Osteoporosis Trial Finds Patients Transitioned From Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density Versus Those Continuing on Alendronate
- Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
- Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison With Weekly Alendronate (FOSAMAX(R))
- Forteo Increases Bone Mineral Density in Osteoporosis Patients
- Providence Health System Research Team Demonstrates Investigational Osteoporosis Therapy Increases Bone Mineral Density
- Impact of Recreational Physical Activity on Bone Mineral Density in Middle-Aged Men
- Amgen investigational therapy for bone loss, denosumab, show increased bone mineral density
- Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density With Twice-Yearly Dosing
- Associated Loss of Fat-Free Mass and Bone Mineral Density in Chronic Obstructive Pulmonary Disease
 |
 |
User Comments (0)
RSS Feeds